194 related articles for article (PubMed ID: 24751980)
1. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
2. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
3. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
4. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
Huang H; Wang L; Li M; Wang X; Zhang L
World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Tang Y; Liu F; Zheng C; Sun S; Jiang Y
J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
[TBL] [Abstract][Full Text] [Related]
7. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
[TBL] [Abstract][Full Text] [Related]
9. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
10. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin.
Ma X; Bai Y
Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041
[TBL] [Abstract][Full Text] [Related]
11. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.
Wang Y; Wang X; Zhao H; Liang B; Du Q
J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100
[TBL] [Abstract][Full Text] [Related]
12. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin.
Chen X; Jiang Y; Huang Z; Li D; Chen X; Cao M; Meng Q; Pang H; Sun L; Zhao Y; Cai L
Sci Rep; 2016 Jan; 6():19455. PubMed ID: 26781643
[TBL] [Abstract][Full Text] [Related]
13. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells.
Wang Q; Cao W; Su Q; Liu Z; Zhang L
World J Surg Oncol; 2014 Apr; 12():124. PubMed ID: 24767179
[TBL] [Abstract][Full Text] [Related]
14. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
He Y; Fan SZ; Jiang YG
Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
[TBL] [Abstract][Full Text] [Related]
15. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
He L; Du ZD; Wang Y; Meng RQ; Zhao WW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells.
Dong A; Kong M; Ma Z; Qian J; Cheng H; Xu X
Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):497-504. PubMed ID: 18535748
[TBL] [Abstract][Full Text] [Related]
18. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
19. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
20. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
Wang M; Liu ZM; Li XC; Yao YT; Yin ZX
J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
